Literature DB >> 24248959

Inspiration from old dyes: tris(stilbene) compounds as potent gram-positive antibacterial agents.

Ramiz A Boulos1, Nikki Y T Man, Nigel A Lengkeek, Katherine A Hammer, Niki F Foster, Natalie A Stemberger, Brian W Skelton, Pan Yu Wong, Boris Martinac, Thomas V Riley, Allan J McKinley, Scott G Stewart.   

Abstract

Herein we describe the preparation and structure-activity relationship studies on range of stilbene based compounds and their antibacterial activity. Two related compounds, each bearing carboxylic acid moieties, exhibit good activity against several bacterial strains, including methicillin-resistant Staphylococcus aureus MRSA (ATCC 33592 and NCTC 10442). Compound 10 was most active against Moraxella catarrhalis with minimum inhibitory concentrations (MICs) of 0.12-0.25 μg mL(-1) and against Staphylococcus spp. with MICs ranging from 2-4 μg mL(-1). The derivative 17 showed increased activity with MICs of 0.06-0.25 μg mL(-1) against M. catarrhalis and 0.12-1 against Staphylococcus spp. This level of activity is similar to that reported for S. aureus for antibiotics, such as vancomycin, with MICs of ≤2.0 μg mL(-1) and clindamycin with MICs of ≤0.5 μg mL(-1). As an indicator of toxicity, 17 was tested for its ability to lyse sheep erythrocytes, and showed low haemolytic activity. Such results highlight the value of tris(stilbene) compounds as antibacterial agents providing suitable properties for further development.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Heck cross-coupling; MRSA; antibacterial; biological activity; stilbenes

Mesh:

Substances:

Year:  2013        PMID: 24248959     DOI: 10.1002/chem.201303119

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  5 in total

Review 1.  Life with Bacterial Mechanosensitive Channels, from Discovery to Physiology to Pharmacological Target.

Authors:  Paul Blount; Irene Iscla
Journal:  Microbiol Mol Biol Rev       Date:  2020-01-15       Impact factor: 11.056

2.  A new antibiotic with potent activity targets MscL.

Authors:  Irene Iscla; Robin Wray; Paul Blount; Jonah Larkins-Ford; Annie L Conery; Frederick M Ausubel; Soumya Ramu; Angela Kavanagh; Johnny X Huang; Mark A Blaskovich; Matthew A Cooper; Andres Obregon-Henao; Ian Orme; Edwin S Tjandra; Uwe H Stroeher; Melissa H Brown; Cindy Macardle; Nick van Holst; Chee Ling Tong; Ashley D Slattery; Christopher T Gibson; Colin L Raston; Ramiz A Boulos
Journal:  J Antibiot (Tokyo)       Date:  2015-02-04       Impact factor: 2.649

3.  Zolav(®) (a p-carboethoxy-tristyrylbenzene derivative) [corrected]: a new antibiotic for the treatment of acne.

Authors:  Alexa Dinant; Ramiz A Boulos
Journal:  Drug Des Devel Ther       Date:  2016-03-22       Impact factor: 4.162

4.  Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.

Authors:  Shasha Rao; Clive A Prestidge; Lynn Miesel; Deb Sweeney; Dean L Shinabarger; Ramiz A Boulos
Journal:  J Antibiot (Tokyo)       Date:  2016-05-18       Impact factor: 2.649

5.  Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound.

Authors:  Nikki Y T Man; Daniel R Knight; Scott G Stewart; Allan J McKinley; Thomas V Riley; Katherine A Hammer
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.